IL133870A0 - Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation - Google Patents
Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparationInfo
- Publication number
- IL133870A0 IL133870A0 IL13387098A IL13387098A IL133870A0 IL 133870 A0 IL133870 A0 IL 133870A0 IL 13387098 A IL13387098 A IL 13387098A IL 13387098 A IL13387098 A IL 13387098A IL 133870 A0 IL133870 A0 IL 133870A0
- Authority
- IL
- Israel
- Prior art keywords
- preparation
- receptor antagonists
- sulphonamide derivatives
- sulphonamide
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/08—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with a hetero atom directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/66—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9714530.4A GB9714530D0 (en) | 1997-07-11 | 1997-07-11 | Novel compounds |
GBGB9724530.2A GB9724530D0 (en) | 1997-11-19 | 1997-11-19 | Novel compounds |
PCT/EP1998/004973 WO1999002502A2 (en) | 1997-07-11 | 1998-07-09 | Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
IL133870A0 true IL133870A0 (en) | 2001-04-30 |
Family
ID=26311860
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL13387098A IL133870A0 (en) | 1997-07-11 | 1998-07-09 | Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation |
Country Status (20)
Country | Link |
---|---|
US (1) | US6316450B1 (hu) |
EP (1) | EP0994862B1 (hu) |
JP (1) | JP2002511097A (hu) |
KR (1) | KR20010021643A (hu) |
CN (1) | CN1087294C (hu) |
AR (1) | AR013199A1 (hu) |
AT (1) | ATE296811T1 (hu) |
AU (1) | AU736256B2 (hu) |
BR (1) | BR9810991A (hu) |
CA (1) | CA2296033A1 (hu) |
DE (1) | DE69830405T2 (hu) |
ES (1) | ES2244082T3 (hu) |
HU (1) | HUP0003073A3 (hu) |
IL (1) | IL133870A0 (hu) |
NO (1) | NO20000108L (hu) |
NZ (1) | NZ501258A (hu) |
PL (1) | PL338016A1 (hu) |
TR (1) | TR200000073T2 (hu) |
TW (1) | TW470743B (hu) |
WO (1) | WO1999002502A2 (hu) |
Families Citing this family (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9801392D0 (en) * | 1998-01-22 | 1998-03-18 | Smithkline Beecham Plc | Novel compounds |
GB9803411D0 (en) * | 1998-02-18 | 1998-04-15 | Smithkline Beecham Plc | Novel compounds |
US6194410B1 (en) | 1998-03-11 | 2001-02-27 | Hoffman-La Roche Inc. | Pyrazolopyrimidine and pyrazolines and process for preparation thereof |
AU5235699A (en) | 1998-07-31 | 2000-02-21 | Eli Lilly And Company | Sulfonamide derivatives |
GB9818914D0 (en) * | 1998-08-28 | 1998-10-21 | Smithkline Beecham Plc | Use |
SE0001899D0 (sv) | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
US6586592B2 (en) | 2000-06-20 | 2003-07-01 | Pharmacia & Upjohn Company | Bis-arylsulfones |
PE20020063A1 (es) | 2000-06-20 | 2002-01-30 | Upjohn Co | Bis-arilsulfonas como ligandos del receptor de 5-ht |
SE0002739D0 (sv) * | 2000-07-21 | 2000-07-21 | Pharmacia & Upjohn Ab | New use |
US6399617B1 (en) * | 2000-07-21 | 2002-06-04 | Biovitrum Ab | Use |
GB0021450D0 (en) * | 2000-08-31 | 2000-10-18 | Smithkline Beecham Plc | Novel compounds |
US7034029B2 (en) | 2000-11-02 | 2006-04-25 | Wyeth | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
EP1341783A1 (en) | 2000-11-21 | 2003-09-10 | Smithkline Beecham Plc | Isoquinoline derivatives useful in the treatment of cns disorders |
EA009647B1 (ru) | 2001-05-11 | 2008-02-28 | Биовитрум Аб | Арилсульфонамидные соединения и их применение для лечения ожирения и диабета типа ii |
US7718650B2 (en) | 2001-05-11 | 2010-05-18 | Biovitrum Ab | Aryl sulfonamide compounds for treating obesity |
AU2002309435B2 (en) * | 2001-06-11 | 2008-08-14 | Biovitrum Ab (Publ) | Substituted sulfonamide compounds, process for their use as medicament for the treatment of CNS disorders, obesity and type II diabetes |
ATE417838T1 (de) * | 2001-08-10 | 2009-01-15 | Hoffmann La Roche | Arylsulfonyl-derivate mit 5-ht 6-rezeptor- affinität |
CA2466490C (en) * | 2001-11-22 | 2009-12-29 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
US7074788B2 (en) | 2001-11-22 | 2006-07-11 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
CA2466491A1 (en) * | 2001-11-22 | 2003-05-30 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
AU2007205749B2 (en) * | 2001-11-22 | 2009-04-23 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
EA200400707A1 (ru) | 2001-11-22 | 2004-10-28 | Биовитрум Аб | Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1 |
WO2003068752A1 (en) * | 2002-02-13 | 2003-08-21 | Glaxo Group Limited | Benzenesulfonamide derivatives as antipsychotic agents |
EP1495004A2 (en) * | 2002-02-13 | 2005-01-12 | Glaxo Group Limited | Benzenesulfonamide derivatives and their use as dopamine d3 and d2 receptor ligands |
DE60304695T2 (de) * | 2002-02-13 | 2006-09-21 | Glaxo Group Ltd., Greenford | 7-arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo[d]azepin-derivate mit 5-hat-6-rezeptor affinität zur behandlung von erkrankungen des zentralnervensystems |
GB0204720D0 (en) * | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Novel use |
US7452888B2 (en) * | 2002-03-27 | 2008-11-18 | Glaxo Group Limited | Quinoline derivatives and their use as 5-ht6 ligands |
WO2003095434A1 (en) | 2002-05-13 | 2003-11-20 | F. Hoffmann-La Roche Ag | Benzoxazine derivatives as 5-ht6 modulators and uses thereof |
AU2003248549B2 (en) | 2002-05-24 | 2010-04-08 | Millennium Pharmaceuticals, Inc. | CCR9 inhibitors and methods of use thereof |
US7943639B2 (en) | 2002-06-20 | 2011-05-17 | Proximagen Limited | Compounds |
EP1897876A3 (en) | 2002-06-20 | 2009-03-18 | Biovitrum AB (publ) | Compounds useful for the treatment of obesity, type II diabetes and CNS disorders |
JP2006505559A (ja) * | 2002-10-18 | 2006-02-16 | エフ.ホフマン−ラ ロシュ アーゲー | 5−ht6受容体親和性を持つ4−ピペラジニルベンゼンスルホニルインドール |
US20070021466A1 (en) * | 2002-11-18 | 2007-01-25 | Solomon Ungashe | CCR2 inhibitors and methods of use thereof |
JP4611746B2 (ja) | 2002-11-18 | 2011-01-12 | ケモセントリックス, インコーポレイテッド | アリールスルホンアミド |
US7741519B2 (en) | 2007-04-23 | 2010-06-22 | Chemocentryx, Inc. | Bis-aryl sulfonamides |
US7420055B2 (en) | 2002-11-18 | 2008-09-02 | Chemocentryx, Inc. | Aryl sulfonamides |
US7227035B2 (en) * | 2002-11-18 | 2007-06-05 | Chemocentryx | Bis-aryl sulfonamides |
WO2004078176A1 (en) * | 2003-03-03 | 2004-09-16 | F. Hoffmann-La Roche Ag | 2,5- and 2,6-substituted tetrahydroisoquinolines for use as 5-ht6 modulators |
GB0305575D0 (en) * | 2003-03-11 | 2003-04-16 | Glaxo Group Ltd | Novel compounds |
TWI289141B (en) * | 2003-03-11 | 2007-11-01 | Hoffmann La Roche F. Ag. | Quinolinone derivatives and uses thereof |
KR101157272B1 (ko) | 2003-07-22 | 2012-06-15 | 아레나 파마슈티칼스, 인크. | 5?ht2a 세로토닌 수용체의 조절자로서 이와 관련된질환의 예방 및 치료에 유용한 디아릴 및 아릴헤테로아릴우레아 유도체 |
SE0303480D0 (sv) | 2003-12-19 | 2003-12-19 | Biovitrum Ab | Benzofuranes |
US7262318B2 (en) * | 2004-03-10 | 2007-08-28 | Pfizer, Inc. | Substituted heteroaryl- and phenylsulfamoyl compounds |
US20050201965A1 (en) * | 2004-03-11 | 2005-09-15 | The Procter & Gamble Company | Personal cleansing compositions |
US7932252B2 (en) * | 2004-05-12 | 2011-04-26 | Chemocentryx, Inc. | Aryl sulfonamides |
US20050288340A1 (en) * | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
JP4975626B2 (ja) | 2004-09-30 | 2012-07-11 | エフ.ホフマン−ラ ロシュ アーゲー | 認知障害の処置用の組成物および方法 |
EP1695971A1 (en) * | 2004-12-30 | 2006-08-30 | Laboratorios Del Dr. Esteve, S.A. | Substituted phenyl-piperazine compounds, their preparation and use in medicaments |
AR054363A1 (es) * | 2005-05-23 | 2007-06-20 | Astrazeneca Ab | Compuestos que exhiben actividad moduladora en el receptor 5-hidroxi-triptamina 6 |
AR054044A1 (es) * | 2005-05-23 | 2007-05-30 | Astrazeneca Ab | Derivados de cromano y tetrahidronaftaleno como moduladores del receptor 5 - ht6; intermediarios en su preparacion; composiciones farmaceuticas que los contienen y su empelo en la fabricacion de medicamentos para el tratamiento de enfermedades del snc y de la obesidad. |
SI1919896T1 (sl) * | 2005-08-12 | 2010-04-30 | Suven Life Sciences Ltd | Aminoaril sulfonamidni derivati kot funkcionalni 5-HT6 ligandi |
US7923566B2 (en) | 2005-08-16 | 2011-04-12 | Suven Life Sciences Limited | Alternative process for the preparation of losartan |
KR20080081178A (ko) | 2005-12-21 | 2008-09-08 | 버텍스 파마슈티칼스 인코포레이티드 | 이온 채널 조절인자로서의 헤테로사이클릭 유도체 |
WO2007133580A2 (en) * | 2006-05-09 | 2007-11-22 | Zelos Therapeutics, Inc. | Use of pth (1-31) and optionally g-csf for hematopoietic stimulation |
PT2114878E (pt) | 2007-01-08 | 2011-03-10 | Suven Life Sciences Ltd | Compostos de 5-(heterociclil)-alquil-n-(arilsulfonil)indol e uso dos mesmos como ligandos de 5-ht6 |
US20100041672A1 (en) * | 2007-03-21 | 2010-02-18 | Glaxo Group Limited | Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome |
PA8775801A1 (es) | 2007-04-06 | 2009-05-15 | Neurocrine Biosciences Inc | Antagonista del receptor de la hormona liberadora de gonadotropina y procedimientos relacionados con los mismos |
CL2008000986A1 (es) | 2007-04-06 | 2008-10-17 | Neurocrine Biosciences Inc | COMPUESTO DERIVADO DE HETEROCICLOS DE NITROGENO, AGONISTAS DEL RECEPTOR GnRH; COMPOSICION FARMACEUTICA QUE COMPRENDE A DICHO COMPUESTO; Y USO PARA TRATAR UNA AFECCION RELACIONADA CON LAS HORMONAS SEXUALES, ENDOMETRIOSIS, DISMENORREA, ENFERMEDAD DE OV |
BRPI0809873A2 (pt) | 2007-05-03 | 2018-11-13 | Suven Life Sciences Ltd | "composto, processo para a preparação do composto, método para o tratamento de uma desordem do sistema nervoso central, composição farmacêutica, uso do composto, método para testar antagonistas e antagonistas com seletividade para o receptor 5-th6 e método de tratamento" |
US7776877B2 (en) * | 2007-06-22 | 2010-08-17 | Chemocentryx, Inc. | N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides |
DK2200980T3 (da) | 2007-10-26 | 2011-11-21 | Suven Life Sciences Ltd | Aminoarylsulfonamidforbindelser og deres anvendelse som 5-HT6-ligander |
EP2508177A1 (en) | 2007-12-12 | 2012-10-10 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
EP2103596A1 (en) | 2008-03-18 | 2009-09-23 | Laboratorios Del. Dr. Esteve, S.A. | Process for the preparation of N-(phenylethyl) anilines salts and solvates thereof useful as serotonin 5-HT6 antagonists |
US20110021538A1 (en) | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
WO2009128058A1 (en) | 2008-04-18 | 2009-10-22 | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al | Psycho-pharmaceuticals |
DE102008022221A1 (de) | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
US8318725B2 (en) | 2008-09-17 | 2012-11-27 | Suven Life Sciences Limited | Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands |
JP5536781B2 (ja) | 2008-09-17 | 2014-07-02 | スヴェン・ライフ・サイエンシズ・リミテッド | アリールスルホンアミドアミン化合物および5−ht6リガンドとしてのそれらの使用 |
US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
UA100192C2 (en) | 2008-11-11 | 2012-11-26 | УАЙТ ЭлЭлСи | 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands |
US8343959B2 (en) | 2009-04-30 | 2013-01-01 | Abbott Gmbh & Co. Kg | N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor |
UA107080C2 (uk) * | 2009-04-30 | 2014-11-25 | Сполуки n-феніл(піперазиніл або гомопіперазиніл)бензолсульфонаміду або бензолсульфонілфеніл(піперазину або гомопіперазину), придатні для лікування захворювань, які реагують на модулювання рецептора 5-ht6 серотоніну | |
WO2010125135A1 (en) | 2009-04-30 | 2010-11-04 | Abbott Gmbh & Co. Kg | Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor |
WO2010125136A1 (en) | 2009-04-30 | 2010-11-04 | Abbott Gmbh & Co. Kg | Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor |
EP2456435B1 (en) * | 2009-07-21 | 2015-06-24 | The Board of Trustees of the Leland Stanford Junior University | Heteroaryl benzamides, compositions and methods of use |
US8541404B2 (en) | 2009-11-09 | 2013-09-24 | Elexopharm Gmbh | Inhibitors of the human aldosterone synthase CYP11B2 |
BR112012016526A2 (pt) | 2010-01-05 | 2018-11-06 | Suven Life Sciences Ltd | composto, processo para a preparação de um composto, composição farmacêutica, método para o tratamento de uma desordem do sistema nervoso central |
GB201002563D0 (en) | 2010-02-15 | 2010-03-31 | Cambridge Entpr Ltd | Compounds |
WO2012059432A1 (en) * | 2010-11-01 | 2012-05-10 | Abbott Gmbh & Co. Kg | N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor |
WO2012059431A1 (en) | 2010-11-01 | 2012-05-10 | Abbott Gmbh & Co. Kg | Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor |
WO2013055793A1 (en) | 2011-10-12 | 2013-04-18 | University Of Pittsburg-Of The Commonwealth System Of Higher Education | Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer |
CA2871534A1 (en) * | 2012-04-27 | 2013-10-31 | Glaxo Group Limited | Novel compounds |
US20160257657A1 (en) | 2013-09-20 | 2016-09-08 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer |
JP6564380B2 (ja) | 2013-09-20 | 2019-08-21 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 前立腺癌を治療するための化合物 |
CN104557664B (zh) * | 2013-10-19 | 2020-01-21 | 广东东阳光药业有限公司 | 芳杂环类衍生物及其在药物上的应用 |
MX2016005348A (es) * | 2013-10-25 | 2016-08-11 | Glaxosmithkline Llc | Compuestos novedosos. |
US9663498B2 (en) | 2013-12-20 | 2017-05-30 | Sunshine Lake Pharma Co., Ltd. | Aromatic heterocyclic compounds and their application in pharmaceuticals |
EP3134392B1 (en) * | 2014-04-19 | 2019-01-02 | Sunshine Lake Pharma Co., Ltd. | Sulfonamide derivatives and pharmaceutical applications thereof |
CN105367474A (zh) * | 2014-08-12 | 2016-03-02 | 广东东阳光药业有限公司 | 吲哚啉类衍生物及其在药物上的应用 |
CN104529866A (zh) * | 2014-12-12 | 2015-04-22 | 广东东阳光药业有限公司 | 吲哚类衍生物及其在药物上的应用 |
CN104496987B (zh) * | 2014-12-12 | 2016-03-02 | 广东东阳光药业有限公司 | 取代杂环类化合物及其在药物上的应用 |
EP4119141A1 (en) | 2015-06-12 | 2023-01-18 | Axovant Sciences GmbH | Nelotanserin for the prophylaxis and treatment of rem sleep behavior disorder |
JP2018520187A (ja) | 2015-07-15 | 2018-07-26 | アクソヴァント サイエンシーズ ゲゼルシャフト ミット ベシュレンクテル ハフツングAxovant Sciences GmbH | 神経変性疾患と関連する幻覚の予防および処置のために有用な5−ht2aセロトニン受容体のモジュレーターとしてのジアリールおよびアリールヘテロアリール尿素誘導体 |
US10568882B2 (en) | 2015-08-21 | 2020-02-25 | Srx Cardio, Llc | Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use |
US10865185B2 (en) | 2015-08-21 | 2020-12-15 | Srx Cardio, Llc | Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity |
US10821106B2 (en) | 2015-08-21 | 2020-11-03 | Srx Cardio, Llc | Composition and methods of use of novel phenylalanine small organic compounds to directly modulate PCSK9 protein activity |
US20190119236A1 (en) | 2016-02-23 | 2019-04-25 | Portola Pharmaceuticals, Inc. | Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9) |
US10980806B2 (en) | 2016-03-24 | 2021-04-20 | University of Pittsburgh—of the Commonwealth System of Higher Education | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer |
CN111517963A (zh) * | 2020-06-02 | 2020-08-11 | 杭州福莱蒽特科技有限公司 | 环保型2,6-二氯-4-硝基苯胺的制备方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2442851A1 (de) | 1974-09-06 | 1976-03-18 | Hoechst Ag | Basisch substituierte 3-sulfamoylbenzoesaeurederivate und verfahren zu ihrer herstellung |
US5169430A (en) * | 1991-08-09 | 1992-12-08 | Uniroyal Chemical Company, Inc. | Benzenesulfonamide derivatives and methods for their production |
US5834471A (en) * | 1993-08-06 | 1998-11-10 | Smithkline Beecham P.L.C. | Amide derivatives as 5HT1D receptor antagonists |
FI935373A0 (fi) * | 1993-12-01 | 1993-12-01 | Iws International Inc | Kopplingsstycke eller koppling foer ledning |
EP0733048A1 (en) | 1993-12-07 | 1996-09-25 | Smithkline Beecham Plc | Heterocyclic biphenylylamides useful as 5ht1d antagonists |
GB9325827D0 (en) * | 1993-12-17 | 1994-02-23 | Smithkline Beecham Plc | Compounds |
US5972935A (en) | 1995-08-11 | 1999-10-26 | Smithkline Beecham P.L.C. | Biphenyl(thio)amide and bipennylethan(thi) one derivatives, their preparation and their use as 5-HT1D receptor antagonists |
FR2740134B1 (fr) * | 1995-10-18 | 1998-01-09 | Pf Medicament | Derives d'amines cycliques d'aryl-piperazines, leur preparation et les compositions pharmaceutiques les contenant |
WO1997029097A1 (en) | 1996-02-09 | 1997-08-14 | Smithkline Beecham Plc | Sulfonamide derivatives as 5ht7 receptor antagonists |
US5939451A (en) | 1996-06-28 | 1999-08-17 | Hoffmann-La Roche Inc. | Use of sulfonamides |
DZ2376A1 (fr) * | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
CA2274055A1 (en) | 1996-12-19 | 1998-06-25 | Smithkline Beecham P.L.C. | N-piperazin-1-ylphenyl-benzamide derivatives |
-
1998
- 1998-07-09 AT AT98945162T patent/ATE296811T1/de not_active IP Right Cessation
- 1998-07-09 IL IL13387098A patent/IL133870A0/xx unknown
- 1998-07-09 NZ NZ501258A patent/NZ501258A/en unknown
- 1998-07-09 PL PL98338016A patent/PL338016A1/xx unknown
- 1998-07-09 WO PCT/EP1998/004973 patent/WO1999002502A2/en active IP Right Grant
- 1998-07-09 TR TR2000/00073T patent/TR200000073T2/xx unknown
- 1998-07-09 EP EP98945162A patent/EP0994862B1/en not_active Expired - Lifetime
- 1998-07-09 KR KR1020007000201A patent/KR20010021643A/ko not_active Application Discontinuation
- 1998-07-09 ES ES98945162T patent/ES2244082T3/es not_active Expired - Lifetime
- 1998-07-09 JP JP50818699A patent/JP2002511097A/ja not_active Ceased
- 1998-07-09 CA CA002296033A patent/CA2296033A1/en not_active Abandoned
- 1998-07-09 DE DE69830405T patent/DE69830405T2/de not_active Expired - Fee Related
- 1998-07-09 HU HU0003073A patent/HUP0003073A3/hu unknown
- 1998-07-09 BR BR9810991-0A patent/BR9810991A/pt not_active IP Right Cessation
- 1998-07-09 CN CN98806921A patent/CN1087294C/zh not_active Expired - Fee Related
- 1998-07-09 AU AU92578/98A patent/AU736256B2/en not_active Ceased
- 1998-07-09 US US09/462,652 patent/US6316450B1/en not_active Expired - Fee Related
- 1998-07-10 TW TW087111166A patent/TW470743B/zh not_active IP Right Cessation
- 1998-07-10 AR ARP980103372A patent/AR013199A1/es not_active Application Discontinuation
-
2000
- 2000-01-10 NO NO20000108A patent/NO20000108L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
ES2244082T3 (es) | 2005-12-01 |
JP2002511097A (ja) | 2002-04-09 |
CN1087294C (zh) | 2002-07-10 |
KR20010021643A (ko) | 2001-03-15 |
CA2296033A1 (en) | 1999-01-21 |
NZ501258A (en) | 2001-07-27 |
US6316450B1 (en) | 2001-11-13 |
AU9257898A (en) | 1999-02-08 |
PL338016A1 (en) | 2000-09-25 |
BR9810991A (pt) | 2000-08-08 |
EP0994862B1 (en) | 2005-06-01 |
HUP0003073A3 (en) | 2002-10-28 |
WO1999002502A2 (en) | 1999-01-21 |
CN1261883A (zh) | 2000-08-02 |
AR013199A1 (es) | 2000-12-13 |
NO20000108D0 (no) | 2000-01-10 |
TR200000073T2 (tr) | 2000-06-21 |
WO1999002502A3 (en) | 1999-06-03 |
NO20000108L (no) | 2000-01-10 |
AU736256B2 (en) | 2001-07-26 |
EP0994862A2 (en) | 2000-04-26 |
TW470743B (en) | 2002-01-01 |
DE69830405T2 (de) | 2006-01-26 |
HUP0003073A2 (hu) | 2001-01-29 |
DE69830405D1 (de) | 2005-07-07 |
ATE296811T1 (de) | 2005-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL133870A0 (en) | Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation | |
EP1047425A4 (en) | INTEGRIN RECEPTOR ANTAGONISTS | |
IL133235A0 (en) | 1-Amino-alkylcyclohexane nmda receptor antagonists | |
HU9603525D0 (en) | Vironectin receptor antagonists | |
ZA98691B (en) | Use of central cannabinoid receptor antagonists for the preparation of drugs | |
PL329725A1 (en) | Indole derivatives useful as antagonists of endotelin receptor | |
SI1035115T1 (en) | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists | |
EP1007051A4 (en) | INTEGRIN RECEPTOR ANTAGONISTS | |
HU9601529D0 (en) | Pyrimidinedion-, pyrimidinetrion-, triazinedion-, tetrahydro-quinazolinedion- derivatives as alpha-adrenerg receptor antagonists | |
EP1100506A4 (en) | INTEGRIN RECEPTOR ANTAGONISTS | |
EP1105389A4 (en) | INTEGRIN RECEPTOR ANTAGONISTS | |
AU4698299A (en) | 5-HT7 receptor antagonists | |
EP0880511A4 (en) | INTEGRIN RECEPTOR ANTAGONISTS | |
IL132571A0 (en) | Ergoline derivatives and ther use as somatostatin receptor antagonists | |
PL341114A1 (en) | Antagonists of thrombosin receptors | |
EP1027337A4 (en) | Integrin receptor Antagonist | |
PL335100A1 (en) | Oxazolynones as antagonists of 5ht2a receptor | |
PL330708A1 (en) | Derivatives of indolydine useful as antagonists of 5-ht-2c receptor | |
NO963331D0 (no) | 5-Heteroarylindol-derivater som benzodiazepin-reseptorsete-agonister og antagonister | |
PL330796A1 (en) | Derivatives of indolin useful as antagonists of 5-ht-2c receptor | |
AU4980999A (en) | A3 adenosine receptor antagonists | |
AU3935897A (en) | B1-bradykinin receptor antagonists and use thereof | |
AU6826498A (en) | Endotholin receptor antagonists | |
ZA981206B (en) | Use of NMDA receptor antagonist | |
EP0928194A4 (en) | COMPOSITIONS AND METHODS FOR ADMINISTERING INTEGRIN RECEPTOR ANTAGONISTS |